MKA
VRTX icon

M. Kulyk & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

M. Kulyk & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Buy
537
+52
+11% +$23K 0.04% 104
2026
Q1 		$217K Buy
+485
New +$226K 0.04% 113

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

M. Kulyk & Associates's VRTX Position: Q2 2026 in Review

M. Kulyk & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $23K and bringing the position to 537 shares worth $267K. The position accounts for 0.04% of the portfolio, ranked #104.

M. Kulyk & Associates first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • M. Kulyk & Associates held 537 shares of Vertex Pharmaceuticals worth $267K as of Q2 2026.
  • M. Kulyk & Associates bought 52 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23K.
  • Vertex Pharmaceuticals made up 0.04% of M. Kulyk & Associates's portfolio in Q2 2026, its #104 holding.
  • M. Kulyk & Associates first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on M. Kulyk & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.